These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30326507)

  • 1. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 4. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
    McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
    J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 11. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH; Tetzlaff MT; Nelson K; Amaria R; Patel S; Aung PP; Nagarajan P; Torres-Cabala CA; Diab A; Prieto VG; Curry JL
    Int J Dermatol; 2019 Sep; 58(9):1045-1052. PubMed ID: 29152725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
    Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
    JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
    BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
    Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
    Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 20. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.